Background: Venomous snakebites are a common clinical scenario in the Southeastern United States. CroFab® (Crotalidae Polyvalent Immune Fab (Ovine), BTG, Wales, UK) antivenom is indicated in cases involving pit vipers and is known to be expensive. The treatment protocol for snakebites is based on clinically subjective measures triggering the application, or escalation of, antivenom administration. The purpose of this study is to characterize the use of CroFab at our institution and to evaluate the impact of its use regarding cost and overall outcomes. We suspect that it is often used but potentially less often needed. We hypothesized that CroFab use was associated with increased length of stay (LOS) without an observed difference in patient outcomes.
Materials And Methods: A retrospective chart review of snakebite patients at our level-1 trauma center from 2000 to 2016 was performed. Snakebite location, snake species, number of vials of CroFab administered, hospital LOS, intensive care unit (ICU) LOS, and complications were identified for each patient. Patients were divided into CroFab (C) and no CroFab (NC) groups.
Results: One hundred ninety patients with venomous snakebites were included 53.7% of patients received CroFab. There was no difference in the complication rate of C versus NC groups, ( = .1118). CroFab use was associated with longer hospital LOS ( < .0001) and ICU LOS ( < .0001).
Discussion: CroFab use was associated with increased LOS in our patient population. There was no difference in observed outcomes between the C and NC groups. These findings imply that CroFab is potentially over-used in our patient population
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/00031348211054566 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Compartment Syndrome Following Snake Envenomation in the United States: A Scoping Review of the Clinical Literature.
West J Emerg Med
July 2024
Emory University School of Medicine, Department of Emergency Medicine, Atlanta, Georgia.
Article Synopsis
- Local tissue damage from bites by North American Crotalinae snakes can lead to a specific type of compartment syndrome known as venom-induced compartment syndrome (VICS), which differs from other forms of compartment syndrome.
- Treatment approaches for VICS are inconsistent, particularly regarding the use of fasciotomy, and the effects of newer antivenom treatments on patient outcomes are still unclear.
- This review analyzed 19 medical papers from 1980 to 2020, revealing gaps in data reporting and emphasizing the need for more standardized practices and better documentation in managing VICS patients.
Failure of Crotalidae Immune F(ab') Equine Antivenom to Achieve Control in a Southern Pacific Rattlesnake Envenomation.
Ann Emerg Med
December 2022
Division of Medical Toxicology, Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Rattlesnake envenomation can result in significant cutaneous and hematologic toxicity. While Cotalidae polyvalent immune Fab (ovine) antivenom (marketed as CroFab) was available for years, it is associated with increased late hematologic toxicity compared with its predecessor. Consequently, Crotalidae Immune F(ab') equine antivenom [marketed as Anavip; F(ab')AV] has been recently become available.
View Article and Find Full Text PDFFashionably late: A characterization of late coagulopathies in rattlesnake envenomations between Fab and F(ab')2 antivenoms.
Toxicon
June 2022
Arizona Poison and Drug Information Center, 1295, N Martin Ave, Tucson, AZ, USA; Department of Emergency Medicine, University of Arizona College of Medicine, 1501, N Campbell Ave, Tucson, AZ, USA.
Background: Rattlesnake envenomation may lead to a multitude of clinical effects, including a late onset hemorrhage. Laboratory values such as platelets and fibrinogen are commonly used to assess the risk of developing a life-threatening bleed. To date, no specific threshold has been identified that links a lab value to the risk of bleeding.
View Article and Find Full Text PDFPredictors of FabAV use in copperhead envenomation.
Clin Toxicol (Phila)
May 2022
Department of Pediatrics, University of Oklahoma School of Community Medicine, Tulsa, OK, USA.
Context: Crotaline snake envenomation is a serious medical condition affecting thousands of Americans each year. Variation in the treatment of Crotaline snakebites exists among physicians in the United States. Management of copperhead snakebites is controversial with some experts advocating minimal intervention, rarely necessitating antivenom use and, even more rarely, surgical intervention.
View Article and Find Full Text PDFCrotalidae Polyvalent Immune Fab and Cost-Effective Management of Hospital Admissions for Snakebites.
Am Surg
March 2022
Department of Surgery, 12241Mercer University School of Medicine, Atrium Navicent Health, Macon, GA, USA.
Background: Venomous snakebites are a common clinical scenario in the Southeastern United States. CroFab® (Crotalidae Polyvalent Immune Fab (Ovine), BTG, Wales, UK) antivenom is indicated in cases involving pit vipers and is known to be expensive. The treatment protocol for snakebites is based on clinically subjective measures triggering the application, or escalation of, antivenom administration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!